

<!--StartFragment-->RESULT 4

AAE22843

SEQ ID NO: 9 alignment

ID AAE22843 standard; protein; 802 AA.

XX

AC AAE22843;

XX

DT 21-AUG-2002 (first entry)

XX

DE Human phospholipase A2-like enzyme #5.

XX

KW Human; phospholipase A2-like enzyme; PLA2; asthma; cancer; inflammation;
 KW cardiovascular disorder; central nervous system disease; CNS; diabetes;
 KW obesity; chronic obstructive pulmonary disease; overweight; anorexia;
 KW cachexia; wasting disorder; appetite modulation; eating disorder; stroke;
 KW bulimia; obesity; hypertension; type 2 diabetes; gall bladder disease;
 KW coronary artery disease; hyperlipidaemia; osteoarthritis; sleep apnoea;
 KW respiratory disorder; cancer; polycystic ovarian syndrome; pregnancy;
 KW thrombotic disease; menstrual irregularities; hirsutism; depression;
 KW gout; stress incontinence; gene therapy; cytostatic; cardiatic; vulnerary;
 KW nootropic; Anticonvulsant; neuroleptic; tranquilliser; antiinfertility;
 KW analgesic; metabolic; enzyme.

XX

OS Homo sapiens.

XX

PN WO200231162-A2.

XX

PD 18-APR-2002.

XX

PF 09-OCT-2001; 2001WO-EP011642.

XX

PR 10-OCT-2000; 2000US-0238434P.

PR 27-DEC-2000; 2000US-0258051P.

PR 31-AUG-2001; 2001US-0315982P.

XX

PA (FARB) BAYER AG.

XX

PI Zhu Z;

XX

DR WPI; 2002-416866/44.

DR N-PSDB; AAD36478.

XX

PT New human phospholipase A2-like enzyme polypeptides for treating or
 PT preventing cancer, inflammation, and chronic obstructive pulmonary
 PT disease, diabetes, stroke, dementia and obesity.

XX

PS Claim 25; Fig 9; 164pp; English.

XX

CC The present invention relates to novel human phospholipase A2 (PLA2)-like
 CC enzyme polypeptides and their corresponding proteins. PLA2-like sequences
 CC are useful for treating phospholipase A2-like enzyme dysfunction related
 CC diseases such as asthma, cancer, inflammation, cardiovascular disorder,
 CC central nervous system (CNS) disease, diabetes, obesity and chronic
 CC obstructive pulmonary disease. They are useful for treating overweight,
 CC anorexia, cachexia, wasting disorders, appetite suppression, appetite
 CC enhancement, increases or decreases in satiety, modulation of body weight
 CC and/or other eating disorders such as bulimia, obesity/overweight-
 CC associated comorbidities including hypertension, type 2 diabetes, stroke,
 CC coronary artery disease, hyperlipidaemia, gall bladder disease, gout,
 CC osteoarthritis, sleep apnoea and respiratory problems, endometrial,
 CC breast, prostate, colon cancer, thrombotic disease, polycystic ovarian
 CC syndrome, reduced fertility, complications of pregnancy, menstrual

CC irregularities, hirsutism, stress incontinence and depression. Sequences
 CC of the invention are also used in gene therapy. The present sequence is
 CC human PLA2-like protein
 XX
 SQ Sequence 802 AA;

Query Match 97.8%; Score 4184; DB 5; Length 802;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 802; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	17	EASTCWQLTVRVLEARNLRWADLLSEADPYVILQLSTAPGMKFKTKLTDTSHPVWNEAF	76
Db	1	EASTCWQLTVRVLEARNLRWADLLSEADPYVILQLSTAPGMKFKTKLTDTSHPVWNEAF	60
Qy	77	RFLIQSQVKNVLELSIYDEDSVTEDDICFKVLYDISEVLP GKLLRKTF SQSPQGE EELDV	136
Db	61	RFLIQSQVKNVLELSIYDEDSVTEDDICFKVLYDISEVLP GKLLRKTF SQSPQGE EELDV	120
Qy	137	EFLMEETSDRPENLITNKVIVARELSCLDVHLDSTGSTAVVADQDKLELELVKGSYEDT	196
Db	121	EFLMEETSDRPENLITNKVIVARELSCLDVHLDSTGSTAVVADQDKLELELVKGSYEDT	180
Qy	197	QTSFLGTASAFRFHYMAALETELSGR LRSSRSNGWNGDNSAGYLT VPLRPLTIGKEVTMD	256
Db	181	QTSFLGTASAFRFHYMAALETELSGR LRSSRSNGWNGDNSAGYLT VPLRPLTIGKEVTMD	240
Qy	257	VPAPNAPGVRLQLKAEGCPEELAVHLGFNLCAEEQAFLSRRKQV VAKALKQALQLDRDLQ	316
Db	241	VPAPNAPGVRLQLKAEGCPEELAVHLGFNLCAEEQAFLSRRKQV VAKALKQALQLDRDLQ	300
Qy	317	EDEVPPVVGIMATGGGARAMTSLYGHLLALQKLGLLDCV TYFSGISGSTWTMAHLYGDPEW	376
Db	301	EDEVPPVVGIMATGGGARAMTSLYGHLLALQKLGLLDCV TYFSGISGSTWTMAHLYGDPEW	360
Qy	377	SQRDLEGPIRYAREHLAKSKLEVFS PERLAS YRRELELRAEQGHPTTFVDLWALVLESML	436
Db	361	SQRDLEGPIRYAREHLAKSKLEVFS PERLAS YRRELELRAEQGHPTTFVDLWALVLESML	420
Qy	437	HGQVMDQKLSGQRAALERGQNPLPLYLSLNVKENNLETLD FKEWVEFS PYEVGFLKYGAF	496
Db	421	HGQVMDQKLSGQRAALERGQNPLPLYLSLNVKENNLETLD FKEWVEFS PYEVGFLKYGAF	480
Qy	497	VPPELFGSEFFMGRLMRRIPERICFLEAIWSNIFSLNLLDAWYDLTSSGESWKQH IKDK	556
Db	481	VPPELFGSEFFMGRLMRRIPERICFLEAIWSNIFSLNLLDAWYDLTSSGESWKQH IKDK	540
Qy	557	TRSLEKEPLTTSGTSSRLEASWLQPGTALAQA FKGFLTGRPLHQ RSPNFLQGLQLHQDYC	616
Db	541	TRSLEKEPLTTSGTSSRLEASWLQPGTALAQA FKGFLTGRPLHQ RSPNFLQGLQLHQDYC	600
Qy	617	SHKDFSTWADYQLDSMPSQLTPKEPR LCLVDAA YFINTSSPSMFRPGRRDLILSFDYSL	676
Db	601	SHKDFSTWADYQLDSMPSQLTPKEPR LCLVDAA YFINTSSPSMFRPGRRDLILSFDYSL	660
Qy	677	SAPFEALQQT ELYCRARGLPFPRVEPSQDQH QPRECHLFSDPACPEAPILLHFPLVNAS	736
Db	661	SAPFEALQQT ELYCRARGLPFPRVEPSQDQH QPRECHLFSDPACPEAPILLHFPLVNAS	720
Qy	737	FKDHSAPGVQRSPAELQGGQVDLTGATCPYTL SNMTYKEEDFERLLRLSDYNVQTSQGAI	796
Db	721	FKDHSAPGVQRSPAELQGGQVDLTGATCPYTL SNMTYKEEDFERLLRLSDYNVQTSQGAI	780

Qy	797	LQALRTALKHRTLEARPPRAQT	818
Db	781	LQALRTALKHRTLEARPPRAQT	802

<!--EndFragment-->